HALIFAX,
Dec. 2, 2013 /CNW/ - MedMira, Inc.
(MedMira) (TSXV: MIR), a developer of rapid diagnostic technology
and solutions, today announced that Dan
Frid, the Company's Chief Financial Officer, will leave the
Company effective December 6, 2013,
to pursue other professional opportunities. Frid has served
as MedMira's CFO since July 2010,
with overall responsibility for financial and accounting
operations, strategic fiscal planning, accountability and analysis,
and contributed to various corporate support and administrative
functions.
"We would like to thank Dan for his leadership
and contributions to the Company," said Hermes Chan, Chief Executive Officer of MedMira
Inc. "Dan has been committed to this organization and has added to
the strength of its financial position. We wish him all the
best in his future endeavours."
The Company has identified a new CFO and a
detailed announcement will be issued shortly.
About MedMira
MedMira is the leading developer and
manufacturer of flow-through rapid diagnostics and technologies.
MedMira is the only Canadian company to be awarded US Army
contracts for the development of rapid tests for HIV and Hepatitis
viruses. The Company's testing solutions provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis for
diseases such as HIV and hepatitis C in just three minutes. The
Company's tests are sold under the Reveal®, Multiplo™ and Miriad
brands in global markets. MedMira is located in Halifax, Nova Scotia, Canada.
www.medmira.com.
This news release contains forward-looking
statements, including statements relating to growth in the
Company's business, earnings and profitability, and trends in
demand for the Company's products, which involve risk and
uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
